Abstract
IMPORTANCE:
Given the critical role that iron plays in neurodevelopment,
an association between prenatal iron deficiency and later risk of
neurodevelopmental disorders, such as autism spectrum disorder (ASD),
attention-deficit/hyperactivity disorder (ADHD), and intellectual disability
(ID), is plausible.
OBJECTIVE:
To test the a priori hypothesis that anemia diagnosed in
mothers during pregnancy is associated with an increased risk of ASD, ADHD, and
ID in offspring and that the magnitude of the risk varies with regard to the timing
of anemia in pregnancy.
DESIGN, SETTING, AND PARTICIPANTS:
This cohort study used health and population register data
from the Stockholm Youth Cohort to evaluate 532 232 nonadoptive children born
from January 1, 1987, to December 31, 2010, in Sweden, with follow-up in health
registers until December 31, 2016. Data analysis was performed from January 15,
2018, to June 20, 2018.
EXPOSURES:
Registered diagnoses of anemia during pregnancy. Gestational
timing of the first recorded anemia diagnosis (≤30 weeks or >30 weeks) was
considered to assess potential critical windows of development.
MAIN OUTCOMES AND MEASURES:
Registered diagnoses of ASD, ADHD, or ID or co-occurring
combinations of these disorders.
RESULTS:
The cohort included 532 232 individuals (272 884 [51.3%]
male) between 6 and 29 years of age at the end of follow-up (mean [SD] age,
17.6 [7.1] years) and their 299 768 mothers. The prevalence of ASD, ADHD, and
ID was higher among children born to mothers diagnosed with anemia within the
first 30 weeks of pregnancy (4.9% ASD, 9.3% ADHD, and 3.1% ID) compared with
mothers with anemia diagnosed later in pregnancy (3.8% ASD, 7.2% ADHD, and 1.1%
ID) or mothers not diagnosed with anemia (3.5% ASD, 7.1% ADHD, and 1.3% ID).
Anemia diagnosed during the first 30 weeks of pregnancy but not later was
associated with increased risk of diagnosis of ASD (odds ratio [OR], 1.44; 95%
CI, 1.13-1.84), ADHD (OR, 1.37; 95% CI, 1.14-1.64), and ID (OR, 2.20; 95% CI,
1.61-3.01) in offspring in models that included socioeconomic, maternal, and
pregnancy-related factors. Early anemia diagnosis was similarly associated with
risk of ASD (OR, 2.25; 95% CI, 1.24-4.11) and ID (OR, 2.59; 95% CI, 1.08-6.22)
in a matched sibling comparison. Considering mutually exclusive diagnostic
groups, we observed the strongest association between anemia and ID without
co-occurring ASD (OR, 2.72; 95% CI, 1.84-4.01). Associations of these disorders
with anemia diagnosed later in pregnancy were greatly diminished.
CONCLUSIONS AND RELEVANCE:
In contrast to maternal anemia diagnosed toward the end of
pregnancy, anemia diagnosed earlier in pregnancy was associated with increased
risk of the development of ASD, ADHD, and particularly ID in offspring. Given
that iron deficiency and anemia are common among women of childbearing age, our
findings emphasize the importance of early screening for iron status and
nutritional counseling in antenatal care.
Maher GM, O'Keeffe GW, Dalman C, Kearney PM, McCarthy FP,
Kenny LC, Khashan AS. Association between preeclampsia and autism spectrum
disorder: a population-based study. J Child Psychol Psychiatry. 2019 Sep
17. doi:10.1111/jcpp.13127. [Epub ahead of print]
Abstract
BACKGROUND:
The environmental contribution of autism spectrum disorder
(ASD) is approximately 17%-50%, highlighting the importance of investigating
factors potentially contributing to the likelihood of its development, and of
gaining a greater understanding of the pathogenesis surrounding ASD. The
objective of this study was to examine the association between preeclampsia and
ASD using a population-based cohort study.
METHODS:
All singleton live births in Sweden from 1982 to 2010 were
included, using data from Swedish National Registers. Exposures of interest
included: (a) preeclampsia (classified according to ICD-8, ICD-9 and ICD-10)
and (b) preeclampsia and small for gestational age (SGA) combined, used as a
proxy for preeclampsia with placental dysfunction. ASD status was based on
ICD-9 and ICD-10. The cohort consisted of 2,842,230 children, with 54,071 cases
of ASD. Follow-up began from the child's first birthday, and data were censored
at first diagnosis of ASD, death, migration or end of study period (31st
December 2016). We conducted multivariate Cox proportional hazards regression
analysis, adjusting for several perinatal and sociodemographic factors,
selected a priori. We further controlled for shared genetic and familial
confounding using sibling-matched analysis.
RESULTS:
In the adjusted Cox proportional hazards regression
analysis, preeclampsia was associated with a 25% increase in the likelihood of
ASD (Hazard Ratio (HR): 1.25, 95% CI:1.19, 1.30) compared with those unexposed
to preeclampsia, while in the sibling-matched analysis the HR was 1.17 (95% CI:
1.06, 1.28). The HR for preeclampsia and SGA combined was 1.66 (95% CI: 1.49,
1.85) in the adjusted Cox model and 1.95 (95% CI: 1.53, 2.48) in the
sibling-matched analysis.
CONCLUSIONS:
Exposure to preeclampsia or preeclampsia/SGA (i.e. SGA baby
exposed to preeclampsia) was associated with ASD. The stronger association with
preeclampsia/SGA than preeclampsia alone suggests that placental pathology may
be a mechanism for the increased likelihood of ASD.
Courtesy of: https://www.mdlinx.com/journal-summaries/autism-spectrum-disorder-preeclampsia-epidemiology/2019/09/24/7579393?spec=neurology
See: https://childnervoussystem.blogspot.com/2019/08/hemoglobin-a1c-levels-during-pregnancy.html
https://childnervoussystem.blogspot.com/2018/12/association-of-prenatal-exposure-to-air.html
https://childnervoussystem.blogspot.com/2017/06/prenatal-fever-and-autism-risk.html
https://childnervoussystem.blogspot.com/2016/01/maternal-antidepressants-and-autism.html
See: https://childnervoussystem.blogspot.com/2019/08/hemoglobin-a1c-levels-during-pregnancy.html
https://childnervoussystem.blogspot.com/2018/12/association-of-prenatal-exposure-to-air.html
https://childnervoussystem.blogspot.com/2017/06/prenatal-fever-and-autism-risk.html
https://childnervoussystem.blogspot.com/2016/01/maternal-antidepressants-and-autism.html
No comments:
Post a Comment